Clarametyx 2021-05: Dose Ranging Efficacy Study in the Murine Lung Infection Model with Pseudomonas Aeruginosa

Project Details

StatusFinished
Effective start/end date11/08/21 → 9/07/22

Funding

  • Clarametyx Biosciences, Inc.: $11,696.62